about
[Successful Management by Immunoglobulin for Sunitinib-Induced Thrombocytopenia in a Patient with Advanced Metastatic Renal Cell Carcinoma].[A Case Report of Suspected Tuberculous Granuloma in the Kidney after BCG Perfusion Therapy for Urothelial Carcinoma of the Renal Pelvis].Trpm7 Protein Contributes to Intercellular Junction Formation in Mouse UrotheliumRelationship between overactive bladder and irritable bowel syndrome: a large-scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria.Causative significance of bladder blood flow in lower urinary tract symptoms.Effectiveness of physical activity as primary preventive care for lower urinary tract symptoms in elderly people through the "Muscle Enhancing Club".Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.Association between Chronic Periodontal Disease and Lower Urinary Tract Symptoms in Both Sexes.Bladder function in 17β-estradiol-induced nonbacterial prostatitis model in Wistar rat.Kohki tea protects the rabbit bladder from ischemia/reperfusion-induced contractile dysfunction.The impact of abdominal aortic calcification and visceral fat obesity on lower urinary tract symptoms in patients with benign prostatic hyperplasia.Effect of tamsulosin on bladder blood flow and bladder function in a rat model of bladder over distention/emptying induced bladder overactivity.Effect of imidafenacin on nocturia and sleep disorder in patients with overactive bladder.Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.Improvement of Overactive Bladder Symptoms and Bladder Ischemia with Dutasteride in Patients with Benign Prostatic Enlargement.Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study.Effects of chronic treatment with cilostazol, a phosphodiesterase 3 inhibitor, on female rat bladder in a partial bladder outlet obstruction model.Combination of GnRH Antagonist Degarelix and Antiandrogen Is Effective in PSA Reduction and Bone Management in Patients with Prostate Cancer.[Perioperative complications of transurethral resection of bladder tumor in patients receiving antithrombotic therapy].Analysis of bladder vascular resistance before and after prostatic surgery in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction[Solitary fibrous tumor of the adrenal gland with renal cell carcinoma and angiomyolipoma at the same time; a case report][The development and utility of new uroflowmetry measurement by wearable airborne ultrasound Doppler system][Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder]Effect of supplementation with hydrogen-rich water in patients with interstitial cystitis/painful bladder syndromeEffect of PDE-5 inhibitors on lower urinary tract symptoms in patients with benign prostatic hyperplasiaUrodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow studyInfluence of alpha-adrenoceptor antagonists therapy on stool form in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasiaVoiding time as a predictor for urinary tract function and health status[Successful conservative management of blunt renal rupture in a girl][Efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder: videourodynamic evaluation]
P50
Q33431069-0AC9776A-7E83-41B6-8E48-F8D8BDE47BBCQ35942195-5FA0DC31-32DA-46C1-9849-F88C61250965Q36444212-C79FFF2F-5058-463C-AD6E-6D2FFDF18990Q36844517-5A1FDE54-640B-435A-A55E-03764B67CAD7Q37965273-0958DC1C-F7AE-4437-BE8B-10680599C047Q38661449-E3E68594-CE8D-4472-8F9A-C49708EAF58CQ39203746-3852BF96-0A9B-4239-8446-7DCCB7E6B8ABQ40215434-2EB7E983-50AE-4D40-913C-6A69525CB3BAQ43689907-4B8E982C-EB9F-47CF-B49D-C2991CD08F12Q44180307-2E84B241-7CCF-402A-B02C-A7C250E514ABQ48073853-C78FA04E-6F2C-4EA7-96BC-FDBC13011EA1Q48220285-57EB03CF-CB70-44AB-ABB7-8491EADE3E3CQ48231452-F788C438-9594-4EE1-A53D-60535CDCE387Q48795592-925E044D-7226-423D-9AE5-3217C13B33ACQ48902550-E0F04FC3-1650-419A-9CC6-6B16C0099D9CQ48970211-92F92B2E-2BF2-4286-8B59-4A0B7371FCB5Q51157247-9E3DF0BF-4E8D-4DEB-87B2-A11BBD8EB538Q51701208-F3866BDA-6D16-4A1B-9AE6-93C7EAECD747Q53660825-E4D452FA-2CD6-4E8C-BD89-28A156909259Q83842870-2FF5268F-1704-4CDE-B4E3-9C7A317D07B3Q84759174-7C75C93E-402B-4E1B-8298-709CBD771E47Q85196380-0F7BA603-C94E-4D55-8D24-7B3D2D16FD64Q85196390-9C17AF47-1B7E-4816-A5A3-4B08DCECD4DDQ86042290-2C40420B-C0C8-4AD9-8282-2A9FCFC58BAFQ87053697-5BDC49A9-F513-43C3-B95C-D71EA5BDD9F0Q87106199-0A355BC4-651D-4CDD-AAED-E2F54CB98994Q92975917-222AF242-FDB8-4AD9-98B6-8917E0307671Q94652250-572302F1-8893-4E15-8BFC-BA02191A3BE1Q95587746-39785B44-7B45-4C49-83A1-768AD112A864Q95605031-54B72C42-9249-4335-BBBD-357A291F641B
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Seiji Matsumoto
@en
Seiji Matsumoto
@nl
type
label
Seiji Matsumoto
@en
Seiji Matsumoto
@nl
prefLabel
Seiji Matsumoto
@en
Seiji Matsumoto
@nl
P31
P496
0000-0002-9941-3758